Liver cancer patients get new hope: study tests two drug cocktails after first treatment fails

NCT ID NCT07537985

Completed Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 200 people with advanced liver cancer whose first treatment (bevacizumab plus sintilimab) stopped working. Researchers compared two second-line options: a PD-1 inhibitor combined with either lenvatinib or regorafenib. The goal was to see which combo works better and is safer. The study is complete, but results are not yet published.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PD-1 inhibitors (such as sintilimab, camrelizumab, pembrolizumab, nivolumab) combined with lenvatinib or regorafenib
What this could lead to: If successful, this could help doctors choose the best second-line treatment for advanced liver cancer patients who have already tried one therapy.
What could go wrong: This is a retrospective study, not a controlled trial, so results may be less reliable. The drugs can cause serious side effects like liver damage or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULCAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULCAR CARCINOMA

Contacts and locations

Locations

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, 510000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.